Template for sharing EMA documents by Industry to support reliance
Submitted by Anonymous (not verified) on 9 April 2026 - 12:15
Template for sharing EMA documents by Industry to support reliance
Clinical Trial Information System (CTIS) - Sponsor Frequently Asked Questions (FAQ)
Submitted by Anonymous (not verified) on 9 April 2026 - 12:00
Clinical Trial Information System (CTIS) - Sponsor Frequently Asked Questions (FAQ)
ECIM 2026 Featured on Medscape
Submitted by Catalina on 9 April 2026 - 11:08
We are pleased to share that ECIM 2026 has been featured in six articles published on Medscape. These articles showcase the different scientific discussions and research presented during the congress.
The Medscape coverage reflects the relevance and impact of the presentations delivered at the ECIM 2026, helping expand their visbility to a wider audience.
Please find the Medscape articles in the link below:
List of medicines currently in PRIME scheme
Submitted by Anonymous (not verified) on 9 April 2026 - 9:15
List of medicines currently in PRIME scheme
Human medicines European public assessment report (EPAR): Sibnayal, potassium citrate,potassium hydrogen carbonate, Date of authorisation: 30/04/2021, Revision: 5, Status: Authorised
Submitted by Anonymous (not verified) on 9 April 2026 - 9:15
Human medicines European public assessment report (EPAR): Sibnayal, potassium citrate,potassium hydrogen carbonate, Date of authorisation: 30/04/2021, Revision: 5, Status: Authorised
List of eligible industry stakeholder organisations
Submitted by Anonymous (not verified) on 9 April 2026 - 8:15
List of eligible industry stakeholder organisations
COVID-19 vaccines: key facts
Submitted by Anonymous (not verified) on 8 April 2026 - 15:50
COVID-19 vaccines: key facts
Human medicines European public assessment report (EPAR): Supemtek, trivalent influenza vaccine (recombinant, prepared in cell culture), Date of authorisation: 30/03/2026, Status: Authorised
Submitted by Anonymous (not verified) on 8 April 2026 - 15:48
Human medicines European public assessment report (EPAR): Supemtek, trivalent influenza vaccine (recombinant, prepared in cell culture), Date of authorisation: 30/03/2026, Status: Authorised
Human medicines European public assessment report (EPAR): Yellox, bromfenac, Date of authorisation: 18/05/2011, Revision: 13, Status: Authorised
Submitted by Anonymous (not verified) on 8 April 2026 - 15:25
Human medicines European public assessment report (EPAR): Yellox, bromfenac, Date of authorisation: 18/05/2011, Revision: 13, Status: Authorised
Human medicines European public assessment report (EPAR): Aripiprazole Zentiva, aripiprazole, Date of authorisation: 25/06/2015, Revision: 14, Status: Authorised
Submitted by Anonymous (not verified) on 8 April 2026 - 14:34
Human medicines European public assessment report (EPAR): Aripiprazole Zentiva, aripiprazole, Date of authorisation: 25/06/2015, Revision: 14, Status: Authorised